| Literature DB >> 30325856 |
Maisam Abu-El-Haija, Anna S Gukovskaya, Dana K Andersen1, Timothy B Gardner2, Peter Hegyi, Stephen J Pandol3, Georgios I Papachristou, Ashok K Saluja4, Vikesh K Singh5, Aliye Uc6, Bechien U Wu7.
Abstract
A workshop was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases to focus on research gaps and opportunities on drug development for pancreatitis. This conference was held on July 25, 2018, and structured into 3 working groups (WG): acute pancreatitis (AP) WG, recurrent AP WG, and chronic pancreatitis WG. This article reports the outcome of the work accomplished by the AP WG to provide the natural history, epidemiology, and current management of AP; inform about the role of preclinical models in therapy selection; and discuss clinical trial designs with clinical and patient-reported outcomes to test new therapies.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30325856 PMCID: PMC6692135 DOI: 10.1097/MPA.0000000000001175
Source DB: PubMed Journal: Pancreas ISSN: 0885-3177 Impact factor: 3.327